Royalty Pharma Payments To Acquire Equity Securities, FN-NI decreased by 58.3% to $22.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 408.2%, from $4.43M to $22.50M. Over 3 years (FY 2021 to FY 2024), Payments To Acquire Equity Securities, FN-NI shows a downward trend with a -22.7% CAGR.
Increasing payments suggest a strategy of deploying excess cash into financial markets, whereas decreasing payments may signal a shift toward internal asset development.
Cash payments made to acquire equity securities that are not accounted for under the equity method, often representing p...
Common in investment-heavy industries; peers often report this as part of their treasury or investment management function.
investing_payments_to_acquire_equity_securities_fnni| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $100.01M | $35.12M | $34.00M | $28.79M | $0.00 | $25.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $50.00M | $12.50M | $0.00 | $4.43M | $54.00M | $22.50M |
| QoQ Change | — | — | -64.9% | -3.2% | -15.3% | -100.0% | — | -100.0% | — | — | — | — | — | -75.0% | -100.0% | — | >999% | -58.3% |
| YoY Change | — | — | — | — | — | -100.0% | -28.8% | -100.0% | -100.0% | — | -100.0% | — | — | — | — | — | — | +408.2% |